Drug Trial Radar · NCT06310551
First Time in Human Study of Long Acting VH4524184 Formulations
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
Mar 21, 2024
Primary completion
May 28, 2029
Study completion Jun 29, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.
Conditions
- HIV Infections
Interventions
Oral VH4524184Drug
VH4524184 to be taken orally.
VH4524184 Formulation A SCDrug
VH4524184 LAI Formulation A administered subcutaneously.
Placebo Formulation A SCDrug
Placebo Formulation A administered subcutaneously.
rHuPH20Drug
rHuPH20 administered subcutaneously.
VH4524184 Formulation B SCDrug
VH4524184 LAI Formulation B administered subcutaneously.
Placebo Formulation B SCDrug
Placebo Formulation B administered subcutaneously.
VH4524184 Formulation A IMDrug
VH4524184 LAI Formulation A administered intramuscularly.
Placebo Formulation A IMDrug
Placebo Formulation A administered intramuscularly.
VH4524184 Formulation B IMDrug
VH4524184 LAI Formulation B administered intramuscularly.
Placebo Formulation B IMDrug
Placebo Formulation B administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting adverse events (AEs) and related AEsTime frame: From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Percentage of participants with AEs by severityTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Percentage of participants discontinuing the treatment due to AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Change from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Change from baseline in total bilirubin parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Change from baseline in international normalized ratio (INR) parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Maximum toxicity grade increase from baseline in ALT, AST and alkaline phosphataseTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Maximum toxicity grade increase from baseline in total bilirubinTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Maximum toxicity grade increase from baseline in INRTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Percentage of participants reporting injection site reaction (ISR) AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Duration of injection site reaction AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity time (AUC[0-inf]) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Area under the plasma drug concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-t]) of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Maximum observed plasma drug concentration (Cmax) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Cmax of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Time to maximum observed plasma drug concentration (Tmax) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Tmax of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- Apparent terminal half-life (t1/2) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
- t1/2 of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Lenexa, Kansas · Recruiting
GSK Investigational Site
Las Vegas, Nevada · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
GSK Investigational Site
San Antonio, Texas · Recruiting
GSK Investigational Site
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.